Evidence map›Paper›PMID 41910720›Full record

ReviewCurrent medical science2026

Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy.

Zi-Yang Wang, Xiao-Fei Wu, Di-Yi Fu, Xiu-Qi Li, Dan Liu, Shu-Peng Liu, Qian Zhao, Hong-Yun Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zi-Yang Wang *Clinical Pharmacology Research Center, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Xiao-Fei Wu *Clinical Pharmacology Research Center, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Di-Yi FuClinical Pharmacology Research Center, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Xiu-Qi LiClinical Pharmacology Research Center, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Dan LiuCollege of Pharmacy, Shenyang Pharmaceutical University, Shenyang, 110000, China.
Shu-Peng LiuClinical Pharmacology Research Center, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China.
Qian ZhaoClinical Pharmacology Research Center, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China. zhaoqian@pumch.cn.
Hong-Yun WangClinical Pharmacology Research Center, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100730, China. wanghy@pumch.cn.

Funding

National High-Level Hospital Clinical Research Funding 2022-PUMCH-C-059Natural Science Foundation of Beijing Municipality 7252208Noncommunicable Chronic Diseases-National Science and Technology Major Project No.2024ZD0533000The Fundamental Research Funds for the Central Universities, Peking Union Medical College No.3332025127The Prospective Research Program of Changzhou Xitaihu Development Foundation for Frontier Cell-Therapeutic Technology No: 2022-P-006
6 · The paper itself

Abstract

Over the past decade, adeno-associated virus (AAV) vectors have emerged as a powerful tool for in vivo gene transfer, owing to their diverse tissue tropisms, predominantly non-integrative property, and superior safety profile compared with other viral vectors. As of December 2025, ten gene therapies based on recombinant AAV (rAAV) vectors have been approved globally, primarily by the Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA). However, seroprevalence surveys indicate that most individuals carry anti-AAV neutralizing antibodies (NAbs), and nearly 50% of healthy individuals exhibit detectable frequencies of circulating AAV capsid-specific CD8

Indexed as

DependovirusGenetic TherapyGenetic VectorsImmunity, CellularAnimalsAntibodies, NeutralizingCD8-Positive T-LymphocytesGene Therapy AgentsHumansT-Lymphocytes, CytotoxicAntibodies, NeutralizingAdeno-associated virusCD8+ T cellsCellular immunityCytotoxic T lymphocytes (CTLs)Gene therapyImmune evasionImmunogenicityRecombinant adeno-associated virus (rAAV)

Identifiers

PMID41910720

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.